Gestational trophoblastic disease: Current management of hydatidiform mole

BMJ

Volumn 337, Issue 7667, 2008, Pages 453-458

  Sebire, N J ^a   Seckl, M J ^a  

^a CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DACTINOMYCIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; VINCRISTINE; ANTINEOPLASTIC AGENT;

BONE MARROW SUPPRESSION; DISEASE COURSE; ECHOGRAPHY; FOLLOW UP; HAIR LOSS; HUMAN; HYDATIDIFORM MOLE; MOUTH ULCER; NAUSEA; PRIORITY JOURNAL; REVIEW; TROPHOBLASTIC DISEASE; CLINICAL PROTOCOL; FEMALE; GENETICS; METHODOLOGY; PREGNANCY; PRENATAL CARE; RISK FACTOR; UTERUS CANCER;

ANTINEOPLASTIC AGENTS; CLINICAL PROTOCOLS; FEMALE; HUMANS; HYDATIDIFORM MOLE; PREGNANCY; PRENATAL CARE; RISK FACTORS; UTERINE NEOPLASMS;

EID: 50449083151     PISSN: 09598146     EISSN: None     Source Type: Journal    
DOI: 10.1136/bmj.a1193     Document Type: Review

References (34)

1. Szulman AE, Surti U. The syndromes of hydatidiform mole. I. Cytogenetic and morphologic correlations. Am J Obstet Gynecol 1978;131:665-71.
2. Murdoch S, Djuric U, Mazhar B, Seoud M, Khan R, Kuick R, et al. Mutations in NALP7 cause recurrent hydatidiform moles and reproductive wastage in humans. Nat Genet 2006;38:300-2.
3. Fisher RA, Khatoon R, Paradinas FJ, Roberts AP, Newlands ES. Repetitive complete hydatidiform mole can be biparental in origin and either male or female. Hum Reprod 2000;15:594-8.
4. Sebire NJ, Fisher RA, Rees HC. Histopathological diagnosis of partial and complete hydatidiform mole in the first trimester of pregnancy. Pediatr Dev Pathol 2003;6:69-77.
5. Sebire NJ, Rees H. Diagnosis of gestational trophoblastic disease in early pregnancy. Curr Diagn Pathol 2003;8:430-40.
6. KIP2. Am J Surg Pathol 2001;25:1225-30.
7. Fisher RA, Newlands ES. Gestational trophoblastic disease. Molecular and genetic studies. J Reprod Med 1998;43:87-97.
8. Sebire NJ, Foskett M, Fisher RA, Rees H, Seckl M, Newlands E. Risk of partial and complete hydatidiform molar pregnancy in relation to maternal age. Br J Obstet Gynaecol 2002;109:99-102.
9. Smith HO, Kim SJ. Epidemiology. In: Hancock BW, Newlands ES, Berkowitz RS, Cole LA, eds. Gestational trophoblastic disease. 2nd ed. 2003:39-76. www.isstd.org/gtd/contents.html.
10. Sebire NJ, Foskett M, Paradinas FJ, Fisher RA, Francis RJ, Short D, et al. Outcome of twin pregnancies with complete hydatidiform mole and healthy co-twin. Lancet 2002;359:2165-6.
11. Gemer O, Segal S, Kopmar A, Sassoon E. The current clinical presentation of complete molar pregnancy. Arch Gynecol Obstet 2000;264:33-4.
12. Fowler DJ, Lindsay I, Seckl MJ, Sebire NJ. Routine pre-evacuation ultrasound diagnosis of hydatidiform mole: experience of >1000 cases from a regional referral centre. Ultrasound Obstet Gynecol 2006;27:56-60.
13. Johns JN, Greenwold S, Buckley E, Jauniaux E. A prospective study of ultrasound screening for molar pregnancies in missed miscarriages. Ultrasound Obstet Gynecol 2005;25:493-7.
14. Seckl MJ, Gillmore R, Foskett M, Sebire NJ, Rees H, Newlands ES. Routine terminations of pregnancy - should we screen for gestational trophoblastic neoplasia? Lancet 2004;364:705-7.
15. Tidy JA, Hancock BW, Newlands ES. The management of gestational trophoblastic neoplasia. Clinical guideline 38. London: Royal College of Obstetricians and Gynaecologists. 2004.www.rcog.org.uk/resources/Public/pdf/ Gestational_Troph_Neoplasia_No38.pdf.
16. Savage P, Seckl MJ. The role of repeat uterine evacuation in trophoblast disease. Gynecol Oncol 2005;99:251-2.
17. Seckl MJ, Fisher RA, Salemo G, Rees H, Paradinas FJ, Foskett M, et al. Choriocarcinoma and partial hydatidiform moles. Lancet 2000;356:36-9.
18. Mitchell H, Seckl MJ. Discrepancies between commercially available immunoassays in the detection of tumour-derived hCG. Mol Cell Endocrinol 2007;262:310-3.
19. Sebire NJ, Foskett M, Short D, Savage P, Stewart W, Thomson M, et al. Shortened duration of human chorionic gonadotropin surveillance following complete or partial hydatidiform mole: evidence for revised protocol of a UK regional trophoblastic disease unit. Br J Obstet Gynaecol 2007;114:760-2.
20. Wielsma S, Kerkmeijer L, Bekkers R, Pyman J, Tan J, Quinn M. Persistent trophoblast disease following partial molar pregnancy. Aust N Z J Obstet Gynaecol 2006;46:119-21.
21. Sebire NJ, Fisher RA, Foskett M, Rees H, Seckl MJ, Newlands ES. Risk of recurrent hydatidiform mole and subsequent pregnancy outcome following complete or partial hydatidiform molar pregnancy. Br J Obstet Gynaecol 2003;110:22-6.
22. Seckl MJ, Dhillon T, Dancey G, Foskett M, Paradinas FJ, Rees HC, et al. Increased gestational age at evacuation of a complete hydatidiform mole: does it correlate with increased risk of requiring chemotherapy? J Reprod Med 2004;49:527-30.
23. Stone M, Dent J, Kardana A, Bagshawe KD. Relationship of oral contraception to development of trophoblastic tumour after evacuation of a hydatidiform mole. Br J Obstet Gynaecol 1976;83:913-6.
24. Costa HL, Doyle P. Influence of oral contraceptives in the development of post-molar trophoblastic neoplasia: a systematic review. Gynecol Oncol 2006;100:579-85.
25. Seckl MJ, Newlands ES. Presentation and management of persistent gestational trophoblastic disease (GTD) and gestational trophoblastic tumours/neoplasia in the United Kingdom. In: Hancock BW, Seckl MJ, Bericowitz RS, Cole LA, eds. Gestational trophoblastic disease. 3rd ed (in press).
26. McNeish IA, Strickland S, Holden L, Rustin GJ, Foskett M, Seckl MJ, et al. Low-risk persistent gestational trophoblastic disease: outcome after initial treatment with low-dose methotrexate and folinic acid from 1992 to 2000. J Clin Oncol 2002;20:1838-44.
27. Ngan H, Wong LC, Ma HK. Staging and classification systems. In: Hancock BW, Newlands ES, Berkowitz RS, Cole LA, eds. Gestational trophoblastic disease. 2nd ed. 2003:156-74. www.isstd.org/gtd/contents.html.
28. Bower M, Rustin GJ, Newlands ES, Holden L, Short D, Foskett M, et al. Chemotherapy for gestational trophoblastic tumours hastens menopause by 3 years. Eur J Cancer 1998;34:1204-7.
29. Rustin GJ, Newlands ES, Lutz JM, Holden L, Bagshawe KD, Hiscox JG, et al. Combination but not single-agent methotrexate chemotherapy for gestational trophoblastic tumors increases the incidence of second tumors. J Clin Oncol 1996;14:2769-73.
30. Powles T, Savage PM, Stebbing J, Short D, Young A, Bower M, et al. A comparison of patients with relapsed and chemo-refractoiy gestational trophoblastic neoplasia. Br J Cancer 2007;96:732-7.
31. Blagden SP, Foskett MA, Fisher RA, Short D, Fuller S, Newlands ES, et al. The effect of earty pregnancy following chemotherapy on disease relapse and foetal outcome in women treated for gestational trophoblastic tumours. Br J Cancer 2002;86:26-30.
32. Royal College of Obstetricians and Gynaecologists. The management of early pregnancy loss. Clinical guideline 25. 2000. www.rcog.org.uk/ nesources/Public/pdf/green_top_25_management_epl.pdf.
33. Tidy JA, Gillespie AM, Bright N, Radstone CR, Coleman RE, Hancock BW. Gestational trophoblastic disease: a study of mode of evacuation and subsequent need for treatment with chemotherapy. Gynecol Oncol 2000;78:309-12.
34. Foulmann K, Guastalla JP, Caminet N, Trillet-Lenoir V, Raudrant D, Golfier F, et al. What is the best protocol of single-agent methotrexate chemotherapy in nonmetastatic or low-risk metastatic gestational trophoblastic tumors? A review of the evidence. Gynecol Oncol 2006;102:103-10.